Incyte Corporation

Add to watchlist
$82.64
Last updated:06/14/2021
INCY: NASDAQ
Incyte Corporation

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMA… Show more

P/E ratio
37.89x
vs. 25.77x forward

Price is 37.89x times more than EPS $2.18 which eaquals $82.64

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-313.142M
109.493M
+134.97%
446.906M
+308.16%
-295.697M
-166.17%
Cashflow
Sum up money going in and out company
-92.988M
336.227M
+461.58%
710.656M
+111.36%
-124.599M
-117.53%
Total liabilities
All combined debts and obligations
671.953M
719.795M
+7.12%
828.344M
+15.08%
949.65M
+14.64%
Stock exposure in ETFs
ETF
Percentage of ETF
Become a premium member and see all 5 ETFs that include this stock
Company profile
CEO
Mr. Herve Hoppenot
Market capitalization
Large (18.17B)
INCY price history
Loading price stock history...